Royalty Pharma plc (MUN:RPD)

Germany · Delayed Price · Currency is EUR

34.06

+3.65 (12.00%)

At close: Nov 5, 2025

39.48% (1Y)

Market Cap	14.59B
Revenue (ttm)	2.00B
Net Income (ttm)	651.97M
Shares Out	n/a
EPS (ttm)	1.49
PE Ratio	22.38
Forward PE	6.53
Dividend	0.78 (2.30%)
Ex-Dividend Date	Nov 14, 2025

Volume	14
Average Volume	216
Open	32.63
Previous Close	30.41
Day's Range	32.63 - 34.06
52-Week Range	24.46 - 34.06
Beta	n/a
RSI	64.35
Earnings Date	Feb 11, 2026

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. [Read more]

Industry Pharmaceutical Preparations

Founded 1996

Country United Kingdom

Stock Exchange Munich Stock Exchange

Ticker Symbol RPD

Full Company Profile

Financial Performance

In 2024, Royalty Pharma's revenue was $2.26 billion, a decrease of -3.86% compared to the previous year's $2.35 billion. Earnings were $858.98 million, a decrease of -24.31%.

Financial numbers in USD Financial Statements

News

There is no news available yet.